Abstract
T here is growing efforts in developing pharmacological and non-pharmacological therapies directed to decrease both the inflammatory status and the metabolic complications associated to Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA). Nevertheless, these aims provoke a continuum challenge due to the pathophysiological complexity of these rheumatic diseases. SLE consists in the development of auto antibodies, which can affect several systems, such as mucocutaneous, musculoskeletal, renal and central nervous system [1], whereas the main AR features are pain, swelling and morning stiffness in distal joints [2]. Whereas the impact of infections and active disease on mortality has diminished dramatically over the years due to intensive treatment, Cardiovascular Disease (CVD) has emerged as the leading cause of death in these patients [3]. The incidence of myocardial infarction is 5 times as high in patients with lupus as in the general population, and in young women the age-specific incidence is increased by a factor of as much as 50 [4]. Similarly, patients with RA present higher cardiovascular risk, as shown by one to one and a half fold coronary diseases; two fold congestive heart disease and two to three fold thromboembolism [5].
Citation
Costa RG, Dall’Aqua LGC, Simao ANC and Dichi I. Potential Influence of Adiponectin on Systemic Lupus Erythematosus and Rheumatoid Arthritis Therapy. SM J Food Nutri Disord. 2015; 1(1): 1003.